OBU

Discussion in 'Amgen' started by anonymous, May 2, 2018 at 7:55 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Looking for some info on the OBU. Debating on posting for a position here. What is the culture like? Is it true that the old ONYX is run separately? Appreciate any info on pros and cons of joining this BU.
     

  2. anonymous

    anonymous Guest


    All the old onyx folks are long gone. In place are the Amgen loser OBU reps. it's now run like a primary care unit that says its oncology. it's a joke
     
  3. anonymous

    anonymous Guest

    Amgen reps under Amgen leadership which continues to get worse as people leave and new ones come in place. New head of sales is a joke and has one thing in mind. Himself.
     
  4. anonymous

    anonymous Guest

    Amgen reps under Amgen leadership which continues to get worse as people leave and new ones come in place. New head of sales is a joke and has one thing in mind. Himself.
     
  5. anonymous

    anonymous Guest

    who is new head of sales?
     
  6. anonymous

    anonymous Guest

    It is all Amgen all the time. Most of the Onyx people are gone, the culture gone with them. Amgen is as toxic as it gets.
     
  7. anonymous

    anonymous Guest

    They’ve been long gone and replaced by losers like Brian Heath. Look at the marketing directors under him with Chris Seal and Colby Maher - both have no oncology experience and only one has field experience in being a DM but never a rep. I don’t see why Amgen couldn’t get a Genentech or Celgene person in to lead one of the only true oncology therapeutic the company has. For the best oncology drug the company has, instead of getting the “A Team” they went with the not the “B Team” but the “C minus Team”. Onyx gave them H2H superiority data over Velcade but they can’t seem do anything with it. I hope Amgen merges with a company with a bonafide oncology team so they can slim down and fire the entire current OBU leadership team.
     
  8. anonymous

    anonymous Guest

    Most toxic back biting place that I ever worked at and so glad to be gone.
     
  9. anonymous

    anonymous Guest

    C minus team is generous. I would say they are the D minus team at best. F range is what I would give them.

    Kyprolis approves in 2012 and 6 years later hasn’t hit a billion dollars in sales. $10 billion for Onyx should have been 1/3 of that given the current revenue run.
     
  10. anonymous

    anonymous Guest

    Old onyx culture dead long ago. It’s the amgen obu toxicity that reeks. Come if you like working for shitty companies
     
  11. anonymous

    anonymous Guest

    Most oncology reps never go back to selling another primary care driven products. However at Amgen, many leave oncology to go sell at another division because it’s the worst place to be! It’s the worst place to be at Amgen.